QingSong Health Corp (2661) Fair Value & Analysis
Healthcare · HK · Market cap HK$2.0B
Fair value as of: Aug 13, 2026
From 7 valuation models · updated 3 days ago
Share price −21.7% over the past month.
A solid business, screening 44% undervalued on our models.
What matters now
- The price is below even our cautious bear case (HK$6.17). The market is more pessimistic than our downside scenario.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- Solid quality (56/100) at a price below fair value, the discount is the argument here, not the business quality.
Price vs Fair Value (8 months)
White line = price, green steps = our fair value per fiscal year. As of Aug 13, 2026.
How to read this chart
8‑month range HK$5.54 – HK$160.90 · fair‑value band HK$6.17 – HK$9.78 · the HK$5.54 price screens below the HK$7.97 fair value. As of Aug 13, 2026.
Analysis
QingSong Health Corp (2661) currently trades at HK$5.54, while our model-based Fair Value estimate is HK$7.97, implying the stock looks roughly 44.0% undervalued today. The Quality Score stands at 56/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Over the trailing twelve months, QingSong Health Corp generated revenue of HK$1.3B at a net margin of -30.2%. Revenue grew 1.7% year over year. Fundamentals as of Aug 13, 2026
Our scenario range runs from HK$6.17 (bear case) to HK$9.78 (bull case); at HK$5.54, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -64% fair-value upside, at 44%, 2661 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 7 models by family
Widest divergence: Growth DCF (HK$10.21) versus Asset-Based (HK$3.29). Highest evidence: Growth DCF (72).
Notify me when 2661 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 60 · Market factors (momentum, volatility) 0
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
QingSong Health Corporation provides healthcare-related and insurance-related services in China. The company offers digital marketing through healthcare-related educational articles and videos; digital medical research assistance; integrated health service packages with various self-operated and outsourced services; and promotion and consultancy to support …
Full company description
QingSong Health Corporation provides healthcare-related and insurance-related services in China. The company offers digital marketing through healthcare-related educational articles and videos; digital medical research assistance; integrated health service packages with various self-operated and outsourced services; and promotion and consultancy to support early disease screening. It also provides Insurance Brokerage services; and a suite of technical services including smart operations, smart risk control, and smart monitoring through i-Phoenix enterprise service platform. The company was formerly known as QingSongChou Corporation and changed its name to QingSong Health Corporation in September 2020. The company was incorporated in 2014 and is headquartered in Beijing, The People's Republic of China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2025 · reported fiscal years
QingSong Health Corp reported revenue of HK$1.3B in FY2025 versus HK$394M in FY2022, a compound +47.2%/yr. Reported net income was −HK$380M in FY2025.
Watch 2661: get an alert when its fair value changes →
Peer Group
Health Information Services · 125 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Health Information Services median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $241.51 | $91.49 | -62% |
| Pro Medicus Limited PME | A$183.71 | A$23.74 | -87% |
| BrightSpring Health Services, Inc BTSG | $59.68 | $21.31 | -64% |
| HealthEquity, Inc HQY | $105.50 | $56.63 | -46% |
| Hinge Health, Inc HNGE | $86.32 | $24.03 | -72% |
| 10x Genomics, Inc TXG | $58.48 | $17.18 | -71% |
| Waystar Holding WAY | $24.54 | $12.86 | -48% |
| XtalPi Holdings 2228 | HK$8.19 | HK$1.04 | -87% |
| Doximity, Inc DOCS | $24.99 | $25.91 | +4% |
| Privia Health Group PRVA | $21.54 | $5.26 | -76% |
Compare QingSong Health Corp with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is QingSong Health Corp (2661) overvalued or undervalued?
What is the fair value of 2661?
What is the quality score of 2661?
What is the revenue of QingSong Health Corp (2661)?
What is the net profit margin of 2661?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track QingSong Health Corp and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.